• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

POR Gene Record

  • Summary
  • Interactions
  • Claims
  • POR 5447 Druggable Genome

    Alternate Names:

    5447
    CYTOCHROME P450 OXIDOREDUCTASE
    POR
    CPR
    CYPOR
    P450R
    124015
    9208
    ENSG00000127948
    OTTHUMG00000130413
    PA33532
    NADPH--CYTOCHROME P450 REDUCTASE (EC 1.6.2.4) (CPR) (P450R). [SOURCE:UNIPROT/SWISSPROT;ACC:P16435]
    NCPR_HUMAN
    P16435
    NADPH--CYTOCHROME P450 REDUCTASE
    FLJ26468

    Gene Info:

    Human Readable Name DRUGGABLE GENOME
    Interpro Name Oxidoreductase FAD/NAD(P)-binding
    Interpro Type Domain
    Uniprot Evidence 1: Evidence at protein level
    Interpro Acc IPR001433
    Interpro Short Name OxRdtase_FAD/NAD-bd
    Uniprot Status Swiss-Prot
    Gene Biotype PROTEIN_CODING
    (3 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME
    ENZYME

    Publications:

    Woillard JB et al., 2013, Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients., Clin Chem
    Elens L et al., 2013, Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin., Pharmacogenet Genomics
    Oneda B et al., 2009, The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test., Pharmacogenet Genomics
    Cvetković M et al., 2017, Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia., Ther Drug Monit
    Lunde I et al., 2014, The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients., Eur J Clin Pharmacol
    Elens L et al., 2014, Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients., Ther Drug Monit
    Ghodke Y et al., 2012, PharmGKB summary: zidovudine pathway., Pharmacogenet Genomics
    Drogari E et al., 2014, POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia., Pharmacogenomics
    Si S et al., 2019, Impact of single nucleotide polymorphisms on P450 oxidoreductase and peroxisome proliferator-activated receptor alpha on tacrolimus pharmacokinetics in renal transplant recipients., Pharmacogenomics J
    Phupradit A et al., 2018, Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation., Ther Drug Monit
    Lancia P et al., 2018, Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus., Pediatr Nephrol
    Almeida-Paulo GN et al., 2018, Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant., Pharmacogenomics J
    Jannot AS et al., 2016, A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients., Ther Drug Monit
    Zhang JJ et al., 2015, The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients., Int J Clin Pharmacol Ther
    Kuypers DR et al., 2014, Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients., Pharmacogenet Genomics
    Bruckmueller H et al., 2015, Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus., Ther Drug Monit
    Kurzawski M et al., 2014, Impact of PPARA and POR polymorphisms on tacrolimus pharmacokinetics and new-onset diabetes in kidney transplant recipients., Pharmacogenet Genomics
    Lesche D et al., 2014, CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients., Ther Drug Monit
    Elens L et al., 2013, Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus., Pharmacogenet Genomics
    Zhang JJ et al., 2013, Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers., Eur J Clin Pharmacol
    de Jonge H et al., 2011, The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients., Pharmacogenomics
    Kloth JSL et al., 2018, Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib., Pharmacogenomics J
  • TACROLIMUS   POR

    Interaction Score: 3.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30323313 29878980 29399716 28094348 26829596 26227094 25322286 25271728 24921414 24739669 24113216 24061445 23097010 21770725


    Sources:
    PharmGKB

  • MIDAZOLAM   POR

    Interaction Score: 0.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23324807 19801957


    Sources:
    PharmGKB

  • ZIDOVUDINE   POR

    Interaction Score: 0.5

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22960662


    Sources:
    PharmGKB

  • CYCLOSPORINE   POR

    Interaction Score: 0.5

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29135906 24658827 24061445


    Sources:
    PharmGKB

  • SUNITINIB   POR

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28117434


    Sources:
    PharmGKB

  • SIROLIMUS   POR

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23974086


    Sources:
    PharmGKB

  • ATORVASTATIN   POR

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25521355


    Sources:
    PharmGKB

  • NICOTINE   POR

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • Ensembl: ENSG00000127948

    • Version: 101_38

    Alternate Names:
    POR Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • RussLampel: ENSG00000127948

    • Version: 26-July-2011

    Alternate Names:
    ENSG00000127948 Ensembl Gene Id
    NADPH--CYTOCHROME P450 REDUCTASE (EC 1.6.2.4) (CPR) (P450R). [SOURCE:UNIPROT/SWISSPROT;ACC:P16435] Description
    POR Display Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HopkinsGroom: P16435

    • Version: 11-September-2012

    Alternate Names:
    NADPH--CYTOCHROME P450 REDUCTASE Uniprot Protein Name
    POR Uniprot Gene Name
    P16435 Uniprot Accession

    Gene Info:
    Interpro Name Oxidoreductase FAD/NAD(P)-binding
    Interpro Type Domain
    Uniprot Evidence 1: Evidence at protein level

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • PharmGKB: POR

    • Version: 18-August-2020

    Alternate Names:
    PA33532 PharmGKB ID

    Gene Info:

    Publications:
    Woillard JB et al., 2013, Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients., Clin Chem
    Cvetković M et al., 2017, Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia., Ther Drug Monit
    Lunde I et al., 2014, The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients., Eur J Clin Pharmacol

  • HingoraniCasas: ENSG00000127948

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000127948 Gene Symbol
    POR Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HumanProteinAtlas: POR

    • Version: 19.3

    Alternate Names:
    ENSG00000127948 Ensembl Gene ID
    CYPOR Human Protein Atlas Gene Synonym
    FLJ26468 Human Protein Atlas Gene Synonym

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

  • Pharos: POR

    • Version: 01-February-2022

    Alternate Names:
    NADPH--cytochrome P450 reductase Gene Name
    P16435 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21